Inovio Pharmaceuticals (INO) Stock: Buy, Sell, or Hold?
INO - Inovio Pharmaceuticals, Inc.
$1.00
-0.11 (-9.67%)
▼
5d:
-11.66%
30d:
-15.41%
90d:
-14.68%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 09, 2026
25d
Get Alerted When INO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INO is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INO is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INO is currently trading at $1.00, which is considered oversold relative to its 30-day fair value range of $1.11 to $1.29.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $0.95, while resistance sits at $1.26. Short-term momentum is weak, with the stock down 9.7% recently.
Market Sentiment: INO scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+217.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $0.95, while resistance sits at $1.26. Short-term momentum is weak, with the stock down 9.7% recently.
Market Sentiment: INO scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+217.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.11 -
$1.29
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.7%)
- BULLISH: Trading 217.2% below Wall St target ($3.17)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.11 -
$1.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.95
Resistance Level
$1.26
Current Trend
Downtrend
Technical data as of
Oct 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.27
Wall Street Target
$3.17
(+217.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 14, 2026 3:40 AM ET
Data refreshes hourly during market hours. Next update: 4:40 AM
Data refreshes hourly during market hours. Next update: 4:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 51 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 67 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 48 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
19 analysts |
$18 | 43 HOLD |
